Van Campen Liem assisted uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, with the Dutch tax aspects of its public offering with expected aggregate gross proceeds of approximately $75 million. The Van Campen Liem team consisted of Emile Bongers and Can Bahtir.
Please refer to the press release here.